Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Crowther

Showing results (211-220 of 282) with videos related to

Pageof 29
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1993
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma GroupW P Steward, J Verweij, R Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1993
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupW P Steward, J Verweij, R Somers, et al.
Behring Institute Mitteilungen|August 1, 1988
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM Bronchud, J H Scarffe, N Thatcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progressC G Price, A Z Rohatiner, W Steward, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphomaA Rohatiner, F d'Amore, B Coiffier, et al.
Blood|September 15, 1992
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialR Pettengell, H Gurney, J A Radford, et al.
British Journal of Cancer|April 1, 1977
Early central nervous system involvement in adults with acute non-myelogenous leukaemiaT A Lister, J M Whitehouse, M E Beard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cyclesD Murphy, D Crowther, J Renninson, et al.
British Medical Journal|March 18, 1978
MVPP chemotherapy regimen for advanced Hodgkin's diseaseS B Sutcliffe, P F Wrigley, J Peto, et al.
British Journal of Cancer|August 1, 1995
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusionG C Jayson, D Crowther, J Prendiville, et al.
Pageof 29

Showing results (211-220 of 282) with videos related to

Sort By:
Pageof 29
Cancer Chemotherapy and Pharmacology|January 1, 1993
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma GroupW P Steward, J Verweij, R Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1993
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupW P Steward, J Verweij, R Somers, et al.
Behring Institute Mitteilungen|August 1, 1988
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM Bronchud, J H Scarffe, N Thatcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progressC G Price, A Z Rohatiner, W Steward, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphomaA Rohatiner, F d'Amore, B Coiffier, et al.
Blood|September 15, 1992
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialR Pettengell, H Gurney, J A Radford, et al.
British Journal of Cancer|April 1, 1977
Early central nervous system involvement in adults with acute non-myelogenous leukaemiaT A Lister, J M Whitehouse, M E Beard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cyclesD Murphy, D Crowther, J Renninson, et al.
British Medical Journal|March 18, 1978
MVPP chemotherapy regimen for advanced Hodgkin's diseaseS B Sutcliffe, P F Wrigley, J Peto, et al.
British Journal of Cancer|August 1, 1995
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusionG C Jayson, D Crowther, J Prendiville, et al.
Pageof 29